替雷利珠单抗免疫相关性Stevens-Johnson综合征1例

A Case of Tislelizumab Immune-Related Stevens-Johnson Syndrome

摘要: 目的：探讨Stevens-Johnson综合征的病因、临床特征、诊断、治疗及预后。方法：报道一例使用替雷利珠单抗免疫相关性Stevens-Johnson综合征。查阅文献对Stevens-Johnson综合征的病因、临床特征、诊断、治疗及预后进行探讨分析。结果：71岁的肺腺癌患者，使用卡铂 + 白蛋白紫杉醇联合替雷利珠单抗方案化疗2周期后开始出现周身皮损及皮疹、红斑，头面部为著，眼睑及角膜粘膜可见充血红染，有水泡生成，破溃后有黄色组织液流出，1日前出现发热，且体温波动于38℃至38.5℃间，在停止替雷利珠单抗及对症支持治疗后患者的症状得到改善。结论：替雷利珠单抗已被广泛用于各种癌症的治疗，但需要注意的是，这些药物可能会导致免疫相关不良反应。

Abstract: Objective: To investigate the etiology, clinical features, diagnosis, treatment and prognosis of Ste-vens-Johnson syndrome. Methods: To report a case of immune-related Stevens-Johnson syndrome with Tislelizumab. The literature was reviewed to discuss and analyze the etiology, clinical features, diagnosis, treatment, and prognosis of Stevens-Johnson syndrome. Results: A 71-year-old patient with lung adenocarcinoma treated with carboplatin + albumin paclitaxel in combination with Tislelizumab for 2 cycles started to develop peripheral skin lesions and rash and erythema, mainly on the head and face, with congestion and red staining of the eyelids and corneal mucosa, with blis-ter formation and yellow tissue fluid flow after rupture, and a fever that fluctuated between 38˚C and 38.5˚C 1 day ago. The patient’s symptoms improved after discontinuation of Tislelizumab and symptomatic supportive therapy. Conclusion: Tislelizumab has been widely used in the treatment of various cancers, but it is important to note that these drugs may cause immune-related adverse reactions.